Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

A New Managing Director Appointed for Lighthouse Medical Communications US

Lucid Group boost their US operations with the appointment of Andy Willmer as Managing Director for Lighthouse Medical Communications

The magic of mobile working

Lucid Communications Group Ltd. has implemented new ways of agile working across its offices to attract top talent and facilitate the company’s continued growth in the strategic medical communications industry.

Lucid CEO discusses communication excellence in a multimedia world

“The two words 'information' and 'communication' are often used interchangeably, but they signify quite different things. Information is giving out; communication is getting through,” Sydney J. Harris, a renowned Anglo-American...

Lucid tackles Tough Mudder 2017

Last Saturday, twenty enthusiastic Lucidians took on the 2017 London South Tough Mudder Half challenge at the Holmbrush Estate in Surrey. Covering 5 miles and 13 imposing obstacles, the team...

Lucid welcome their graduate Customer Experience Managers

Lucid has had an incredibly busy summer attending recruitment fairs all across the country to find the finest graduate talent for their Futures Executive Programme. As part of its graduate...

Things get competitive at Lucid’s sports day!

While some look back on their school sports days with blissful memories of relay races and tug of war, others are haunted by images of overly competitive parents and injuries...

Lucid’s Creative Services team grows

A vital part to delivering exceptional medical education programmes is the design of clever branding and engaging visual elements. Lucid Group pride themselves in the quality of their digital and...

Leading Edge bolsters its delivery team

After earlier announcements that Lucid Partners was growing its medical writing team, Leading Edge (a Lucid Group company) proudly announces that it is strengthening its delivery team.Francesca Worthington joined Leading Edge...

It’s time to measure outcomes

Lucid launch their new metrics platform

Lucid’s new branding is magic

Lucid Group launch their new branding in this month's PME magazine.